Beam Therapeutics reports that risto-cel, a sickle cell therapy that changes DNA “letters” in blood stem cells, met its pivotal trial’s primary endpoint of at least 12 consecutive months without severe crises; the company is preparing an FDA application
Beam Therapeutics reports that risto-cel, a sickle cell therapy that changes DNA “letters” in blood stem cells, met its pivotal trial’s primary endpoint of at least 12 consecutive months without severe crises; the company is preparing an FDA application
On November 10, Beam announced preliminary results from the BEACON trial: 49 people had received risto-cel, and 31 had completed the follow-up needed to assess the primary endpoint. Independently confirmed results showed that the primary endpoint was met, along with all primary safety endpoints and all secondary efficacy endpoints. Beam will present data from an earlier reporting period at a hematology meeting on December 12.
Risto-cel is made from a patient’s own blood stem cells. The cells are collected, their DNA “letters” are edited outside the body, and they are returned after busulfan chemotherapy makes room in the bone marrow. A base editor makes the change by chemically converting one DNA “letter” into another; CRISPR/Cas9 cuts both DNA strands.
Sickle cell disease is caused by a single-letter substitution in the gene for the beta chain of hemoglobin. The resulting abnormal hemoglobin S clumps into fibers, bending red blood cells into sickle shapes. These cells block blood vessels, causing episodes of pain known as crises. Risto-cel bypasses this substitution by activating HBG1 and HBG2, the genes for fetal hemoglobin, which is the predominant form in the fetus and does not clump. After birth, repressor proteins switch these genes off. One of these proteins, BCL11A, binds to their promoters, the DNA regions that initiate gene activity. The edit changes a letter at the BCL11A binding site, preventing the protein from binding to the promoter.
The edit mimics a naturally occurring condition: in people with hereditary persistence of fetal hemoglobin, HBG genes remain active into adulthood, and the disease is milder. This results from mutations in the promoters of these genes. Some of these mutations disrupt binding sites for repressors, including BCL11A. A base editor can reproduce such mutations without cutting both DNA strands.
In December 2024, Beam reported results for seven treated patients: by the first month, fetal hemoglobin accounted for more than 60 % of the hemoglobin each patient produced. One of the seven died four months after treatment from respiratory failure, which the investigator considered probably related to busulfan. By December 2025, the data covered 31 treated patients. Follow-up averaged 6,6 months, shorter than the period required for the primary endpoint; investigators had recorded no severe crises after the cells engrafted.
BEACON’s primary endpoint is 12 consecutive months without a severe crisis in patients who had experienced at least four such crises in the two years before entering the trial. A crisis is considered severe, for example, if a pain episode requires at least one day in hospital or an opioid in the emergency department. The same primary endpoint was used in the trial that supported the FDA’s December 2023 approval of Casgevy, another gene therapy for sickle cell disease: 29 of 31 patients with sufficient follow-up met the endpoint.
Casgevy also activates fetal hemoglobin through BCL11A, using a different mechanism. Cas9 cuts DNA in a region that enhances BCL11A gene activity in red blood cells, reducing the amount of BCL11A protein in those cells. With risto-cel, the protein remains in the cells but can no longer bind to the HBG1 and HBG2 promoters.
Beam CEO John Evans said: “With these results, we are focused on submitting our planned application as early as the end of the year, which could make it the first application for a base-editing therapy.” For its next generation of therapies, Beam is developing nanoparticles that, according to the company’s description, will deliver the editor directly to blood stem cells inside the body, eliminating the need for transplantation. Its third-quarter report states that such nanoparticles have been identified and are being optimized.
- https://www.globenewswire.com/news-release/2026/11/10/3399328/0/en/beam-therapeutics-announces-positive-topline-pivotal-data-from-beacon-phase-1-2-trial-of-risto-cel-in-patients-with-sickle-cell-disease.html
- https://www.nature.com/articles/s41467-022-34493-1
- https://beamtx.com/wp-content/uploads/2025/12/BEACON-clinical-ASH-poster_final-draft_HIGH-RES-DIGITAL.pdf
- https://beamtx.com/wp-content/uploads/2025/06/BEAM-101-EHA_Final_22May2025.pdf
- https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
- https://beamtx.com/pipeline_candidates/in-vivo-hsc-editing
- https://www.globenewswire.com/news-release/2026/11/03/3394035/0/en/beam-therapeutics-reports-third-quarter-2026-financial-results-and-highlights-clinical-progress-across-base-editing-portfolio.html